Glucagon-like peptide-1 receptor agonists approved for use in the United States

DrugAvailable dosesFrequency and routeDose approved for weight management
Exenatide5 μg, 10 μgTwice daily subcutaneouslyNot approved
Liraglutide0.6 mg, 1.2 mg, 1.8 mgOnce daily subcutaneously0.6 mg once daily for 1 week, increase by 0.6 mg daily at weekly intervals to a target dose of 3 mg once daily
Exenatide extended-release2 mgOnce weekly subcutaneouslyNot approved
Dulaglutide0.75 mg, 1.5 mg, 3 mg, 4.5 mgOnce weekly subcutaneouslyNot approved
Semaglutide0.25 mg, 0.5 mg, 1 mg, 2 mgOnce weeklyTitrate every 4 weeks:
0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg once weekly
Semaglutide, oral3 mg, 7 mg, 14 mgOnce daily by mouthNot approved
Liraglutide-insulin degludec0.36 mg-10 U
0.5 mg-16 U
Once daily subcutaneouslyNot approved
Lixisenatide-insulin glargine5 μg-15 U
10 μg-30 U
Once daily subcutaneouslyNot approved
Tirzepatide2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mgOnce weekly subcutaneouslyNot approved